How to buy Aquestive Therapeutics stock | $3.71

Aquestive Therapeutics, Inc is a biotechnology business based in the US. Aquestive Therapeutics shares (AQST) are listed on the NASDAQ and all prices are listed in US Dollars. Aquestive Therapeutics employs 187 staff and has a trailing 12-month revenue of around 0.00.

Aquestive Therapeutics stock price (NASDAQ: AQST)

Use our graph to track the performance of AQST stocks over time.

Aquestive Therapeutics shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$3.71
52-week range	$3.17 - $9.47
50-day moving average	$3.85
200-day moving average	$4.47
Wall St. target price	$14.67
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-2.61

Buy Aquestive Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Aquestive Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Aquestive Therapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aquestive Therapeutics price performance over time

Historical closes compared with the close of $3.71 from 2021-05-28

1 week (2021-07-23)	N/A
1 month (2021-07-02)	-2.62%
3 months (2021-05-03)	-6.78%
6 months (2021-01-30)	N/A

1 year (2020-07-30)	N/A
2 years (2019-07-30)	N/A
3 years (2018-07-30)	N/A
5 years (2016-07-30)	N/A

Aquestive Therapeutics financials

Revenue TTM	$48.2 million
Gross profit TTM	$32.9 million
Return on assets TTM	-37.14%
Return on equity TTM	0%
Profit margin	-111.86%
Book value	$-0.99
Market capitalisation	$127.3 million

TTM: trailing 12 months

Shorting Aquestive Therapeutics shares

There are currently 2.2 million Aquestive Therapeutics shares held short by investors – that's known as Aquestive Therapeutics's "short interest". This figure is 7% down from 2.4 million last month.

There are a few different ways that this level of interest in shorting Aquestive Therapeutics shares can be evaluated.

Aquestive Therapeutics's "short interest ratio" (SIR)

Aquestive Therapeutics's "short interest ratio" (SIR) is the quantity of Aquestive Therapeutics shares currently shorted divided by the average quantity of Aquestive Therapeutics shares traded daily (recently around 675426.20481928). Aquestive Therapeutics's SIR currently stands at 3.32. In other words for every 100,000 Aquestive Therapeutics shares traded daily on the market, roughly 3320 shares are currently held short.

However Aquestive Therapeutics's short interest can also be evaluated against the total number of Aquestive Therapeutics shares, or, against the total number of tradable Aquestive Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aquestive Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Aquestive Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0653% of the tradable shares (for every 100,000 tradable Aquestive Therapeutics shares, roughly 65 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aquestive Therapeutics.

Find out more about how you can short Aquestive Therapeutics stock.

Aquestive Therapeutics share dividends

We're not expecting Aquestive Therapeutics to pay a dividend over the next 12 months.

Aquestive Therapeutics share price volatility

Over the last 12 months, Aquestive Therapeutics's shares have ranged in value from as little as $3.17 up to $9.465. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aquestive Therapeutics's is 3.5821. This would suggest that Aquestive Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Aquestive Therapeutics overview

Aquestive Therapeutics, Inc. , a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc.

Frequently asked questions

What percentage of Aquestive Therapeutics is owned by insiders or institutions?
Currently 5.757% of Aquestive Therapeutics shares are held by insiders and 45.639% by institutions. How many people work for Aquestive Therapeutics?
Latest data suggests 187 work at Aquestive Therapeutics. When does the fiscal year end for Aquestive Therapeutics?
Aquestive Therapeutics's fiscal year ends in December. Where is Aquestive Therapeutics based?
Aquestive Therapeutics's address is: 30 Technology Drive, Warren, NJ, United States, 07059 What is Aquestive Therapeutics's ISIN number?
Aquestive Therapeutics's international securities identification number is: US03843E1047 What is Aquestive Therapeutics's CUSIP number?
Aquestive Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03843E104